Healthcare Services

Biomarker Clinical Phase Outsourcing Services Market Growth Prospects 2026–2030 with Innovation Trends and Competitive Landscape

March 30, 2026March 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Forecasted Market Value Of The Biomarker Clinical Phase Outsourcing Services Market Across 2026–2030?

The biomarker clinical phase outsourcing services market size has experienced rapid expansion in recent years. It is projected to increase from $11.91 billion in 2025 to $14.62 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 22.7%. This historic growth can be linked to several factors, including the increasing complexity of clinical trial designs, a rise in oncology clinical research activity, the advancement of biomarker-driven drug development, the expansion of translational research programs, and enhanced collaboration with specialized service providers.

The biomarker clinical phase outsourcing services market size is projected to experience substantial growth in the coming years. It is expected to expand to $30.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.1%. This anticipated growth during the forecast period is driven by factors such as the increasing demand for personalized medicine trials, the rising adoption of AI-driven biomarker analytics, the expansion of multi-biomarker clinical studies, growing investments in precision oncology, and an increasing regulatory emphasis on biomarker validation. Significant trends in the forecast period include the increasing outsourcing of biomarker clinical trial activities, the rising use of predictive and prognostic biomarkers, the growing integration of omics-based biomarker analysis, the expansion of companion diagnostics development, and an enhanced focus on precision medicine trials.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15740&type=smp

What Drivers Are Shaping The Future Growth Of The Biomarker Clinical Phase Outsourcing Services Market?

An increase in clinical trials is anticipated to advance the growth of the biomarker clinical phase outsourcing services market in the future. These trials are research endeavors conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. The expansion in clinical trials is driven by advancements in medical research, the rising prevalence of chronic diseases, increased funding from both governmental and private sources, and the growing demand for innovative treatments and therapies. Outsourcing providers often possess specialized knowledge and experience in biomarker discovery, validation, and analysis. This expertise can enhance the quality and reliability of the biomarker data collected during the trial. For instance, in November 2025, according to the National Library of Medicine, a US-based biomedical library reported that ClinicalTrials.gov currently lists 558,242 studies with locations in all 51 states and in 224 countries and territories. Therefore, the rise in clinical trials will propel the growth in the biomarker clinical phase outsourcing services market forward.

What Segmentation Levels Are Considered In The Biomarker Clinical Phase Outsourcing Services Market?

The biomarker clinical phase outsourcing services market covered in this report is segmented –

1) By Type: Surrogate Endpoints, Predictive Biomarker, Prognostic Biomarker, Safety Biomarker, Other Biomarker Types

2) By Service Type: Biomarker Validation, Biomarker Testing Services, Biomarker Sample Analysis

3) By Therapeutic Area: Oncology, Neurology, Cardiology, Autoimmune Diseases, Other Therapeutic Areas

4) By End-User: Pharmaceutical Companies, Biotechnology Companies

Subsegments:

1) By Surrogate Endpoints: Tumor Marker-Based Endpoints, Imaging-Based Endpoints, Genetic or Genomic Markers

2) By Predictive Biomarker: Genetic Predictive Biomarkers, Protein Predictive Biomarkers, Metabolomic Predictive Biomarkers

3) By Prognostic Biomarker: Cancer Prognostic Biomarkers, Cardiovascular Prognostic Biomarkers, Neurological Prognostic Biomarkers

4) By Safety Biomarker: Toxicity Biomarkers, Adverse Drug Reaction Biomarkers, Drug Interaction Biomarkers

5) By Other Biomarker Types: Inflammation Biomarkers, Infectious Disease Biomarkers, Autoimmune Disease Biomarkers

What Key Trends Are Influencing The Development Of The Biomarker Clinical Phase Outsourcing Services Market?

Leading companies in the biomarker clinical phase outsourcing services sector are concentrating on innovations in high-throughput flow cytometry and ELISpot testing to gain a competitive advantage in the market. These methods are utilized for biomarker analysis, enabling swift and accurate assessment of immune responses and cellular markers. For example, in May 2024, KCAS Bio, a U.S.-based bioanalytical Contract Research Organization (CRO) providing GLP/GCP-compliant biomarker and immune-monitoring services, established a global spectral flow cytometry alliance with Crux Biolabs, an Australian CRO specializing in ELISpot and flow cytometry assays. Through this partnership, KCAS Bio strategically placed harmonized spectral cytometers at Crux Biolabs’ facilities, thereby allowing clients to access high-throughput, multiparametric flow cytometry capabilities across the U.S., Europe, and Australia. This collaboration significantly enhances KCAS’s biomarker development and immune-monitoring capacities by facilitating rapid, precise assessment of cellular biomarkers in clinical trials, which empowers clients to generate high-quality data supportive of regulatory submissions and accelerates drug development processes.

Which Leading Firms Are Contributing To The Growth Of The Biomarker Clinical Phase Outsourcing Services Market?

Major companies operating in the biomarker clinical phase outsourcing services market are Thermo Fisher Scientific Inc., Labcorp Drug Development Inc., ICON plc, Eurofins Scientific SE, WuXi AppTec Co. Ltd., Syneos Health Inc., Charles River Laboratories International Inc., Parexel International Corporation, QIAGEN N.V., Medpace Inc., Evotec SE, Precision for Medicine Inc., BioAgilytix Labs LLC, Celerion Inc., Frontage Laboratories Inc., SomaLogic Inc., Metabolon Inc., Caprion Proteomics Inc., Intertek Group plc, Bioclinica Inc., GenScript Biotech Corporation, Selvita S.A.

Read the full biomarker clinical phase outsourcing services market report here:

https://www.thebusinessresearchcompany.com/report/biomarker-clinical-phase-outsourcing-services-global-market-report

Which Geographic Regions Are Influencing Demand In The Biomarker Clinical Phase Outsourcing Services Market?

North America was the largest region in the biomarker clinical phase outsourcing services market in 2025. The regions covered in the biomarker clinical phase outsourcing services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Biomarker Clinical Phase Outsourcing Services Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15740&type=smp

Browse Through More Reports Similar to the Global Biomarker Clinical Phase Outsourcing Services Market 2026, By The Business Research Company

Biomarker Discovery Outsourcing Services Global Market Report

https://www.thebusinessresearchcompany.com/report/biomarker-discovery-outsourcing-services-global-market-report

Clinical Biomarkers Global Market Report

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Biologics Outsourcing Global Market Report

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795